These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 36551696)

  • 21. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
    Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
    Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
    Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
    Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the Hippo pathway in human disease and tumorigenesis.
    Barron DA; Kagey JD
    Clin Transl Med; 2014; 3():25. PubMed ID: 25097728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hippo pathway - brief overview of its relevance in cancer.
    Zygulska AL; Krzemieniecki K; Pierzchalski P
    J Physiol Pharmacol; 2017 Jun; 68(3):311-335. PubMed ID: 28820389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comprehensive evaluation of Hippo pathway silencing in sarcomas.
    Merritt NM; Fullenkamp CA; Hall SL; Qian Q; Desai C; Thomason J; Lambertz AM; Dupuy AJ; Darbro B; Tanas MR
    Oncotarget; 2018 Aug; 9(60):31620-31636. PubMed ID: 30167083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.
    Wang C; Gu C; Jeong KJ; Zhang D; Guo W; Lu Y; Ju Z; Panupinthu N; Yang JY; Gagea MM; Ng PK; Zhang F; Mills GB
    Cancer Res; 2017 Apr; 77(7):1637-1648. PubMed ID: 28202507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. USP21 regulates Hippo pathway activity by mediating MARK protein turnover.
    Nguyen HT; Kugler JM; Loya AC; Cohen SM
    Oncotarget; 2017 Sep; 8(38):64095-64105. PubMed ID: 28969054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Hippo-YAP pathway: new connections between regulation of organ size and cancer.
    Zhao B; Lei QY; Guan KL
    Curr Opin Cell Biol; 2008 Dec; 20(6):638-46. PubMed ID: 18955139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hippo-YAP signaling pathway: A new paradigm for cancer therapy.
    Ma Y; Yang Y; Wang F; Wei Q; Qin H
    Int J Cancer; 2015 Nov; 137(10):2275-86. PubMed ID: 25042563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unraveling the Biology of Epithelioid Hemangioendothelioma, a TAZ-CAMTA1 Fusion Driven Sarcoma.
    Seavey CN; Pobbati AV; Rubin BP
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the Hippo pathway and mechanisms for controlling cellular localization of YAP/TAZ.
    Kwon H; Kim J; Jho EH
    FEBS J; 2022 Oct; 289(19):5798-5818. PubMed ID: 34173335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DUB1 suppresses Hippo signaling by modulating TAZ protein expression in gastric cancer.
    Wang D; Li Z; Li X; Yan C; Yang H; Zhuang T; Wang X; Zang Y; Liu Z; Wang T; Jiang R; Su P; Zhu J; Ding Y
    J Exp Clin Cancer Res; 2022 Jul; 41(1):219. PubMed ID: 35820928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanisms of the mammalian Hippo signaling pathway.
    Ji XY; Zhong G; Zhao B
    Yi Chuan; 2017 Jul; 39(7):546-567. PubMed ID: 28757470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
    Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
    Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 36. New insights in Hippo signalling alteration in human papillomavirus-related cancers.
    Olmedo-Nieva L; Muñoz-Bello JO; Manzo-Merino J; Lizano M
    Cell Signal; 2020 Dec; 76():109815. PubMed ID: 33148514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.
    Li H; Gumbiner BM
    Mamm Genome; 2016 Dec; 27(11-12):556-564. PubMed ID: 27601049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1.
    Ando T; Arang N; Wang Z; Costea DE; Feng X; Goto Y; Izumi H; Gilardi M; Ando K; Gutkind JS
    Commun Biol; 2021 Nov; 4(1):1237. PubMed ID: 34725466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Hippo signaling pathway provides novel anti-cancer drug targets.
    Bae JS; Kim SM; Lee H
    Oncotarget; 2017 Feb; 8(9):16084-16098. PubMed ID: 28035075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hippo-YAP signaling in digestive system tumors.
    Yin F; Dong J; Kang LI; Liu X
    Am J Cancer Res; 2021; 11(6):2495-2507. PubMed ID: 34249412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.